ALT
Price
$4.08
Change
-$0.03 (-0.73%)
Updated
Jul 25 closing price
Capitalization
330.92M
11 days until earnings call
IMAB
Price
$2.11
Change
-$0.01 (-0.47%)
Updated
Jul 25 closing price
Capitalization
172.3M
37 days until earnings call
Interact to see
Advertisement

ALT vs IMAB

Header iconALT vs IMAB Comparison
Open Charts ALT vs IMABBanner chart's image
Altimmune
Price$4.08
Change-$0.03 (-0.73%)
Volume$2.97M
Capitalization330.92M
I-MAB
Price$2.11
Change-$0.01 (-0.47%)
Volume$105.96K
Capitalization172.3M
ALT vs IMAB Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. IMAB commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and IMAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ALT: $4.11 vs. IMAB: $2.11)
Brand notoriety: ALT and IMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 0% vs. IMAB: 15%
Market capitalization -- ALT: $330.92M vs. IMAB: $172.3M
ALT [@Biotechnology] is valued at $330.92M. IMAB’s [@Biotechnology] market capitalization is $172.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileIMAB’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • IMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, IMAB is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while IMAB’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • IMAB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALT is a better buy in the short-term than IMAB.

Price Growth

ALT (@Biotechnology) experienced а +0.74% price change this week, while IMAB (@Biotechnology) price change was +0.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

IMAB is expected to report earnings on Sep 02, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($331M) has a higher market cap than IMAB($172M). IMAB YTD gains are higher at: 148.235 vs. ALT (-42.996). IMAB has higher annual earnings (EBITDA): -46.92M vs. ALT (-90.75M). IMAB has more cash in the bank: 169M vs. ALT (150M). ALT has less debt than IMAB: ALT (1.59M) vs IMAB (3.68M). ALT has higher revenues than IMAB: ALT (20K) vs IMAB (0).
ALTIMABALT / IMAB
Capitalization331M172M192%
EBITDA-90.75M-46.92M193%
Gain YTD-42.996148.235-29%
P/E RatioN/AN/A-
Revenue20K0-
Total Cash150M169M89%
Total Debt1.59M3.68M43%
FUNDAMENTALS RATINGS
ALT: Fundamental Ratings
ALT
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALTIMAB
RSI
ODDS (%)
Bullish Trend 3 days ago
66%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 21 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
76%
Aroon
ODDS (%)
N/A
Bullish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RBGLY15.140.06
+0.40%
Reckitt Benckiser Group Plc.
CDTAF0.03N/A
+0.30%
INFINITII AI INC.
MMSMY7.60N/A
N/A
Mitsu Mining & Smelting Co., Ltd.
SIRZF10.94N/A
N/A
Sir Rty Income Fund
NDBKY13.47-0.22
-1.61%
Nedbank Group, Ltd.

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with RVPH. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then RVPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
N/A
RVPH - ALT
51%
Loosely correlated
+9.63%
INDP - ALT
45%
Loosely correlated
+0.30%
VERA - ALT
39%
Loosely correlated
-0.32%
KROS - ALT
38%
Loosely correlated
+0.56%
OVID - ALT
36%
Loosely correlated
-10.75%
More

IMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with INDP. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then INDP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
-0.47%
INDP - IMAB
39%
Loosely correlated
+0.30%
RPRX - IMAB
31%
Poorly correlated
+0.22%
ALT - IMAB
31%
Poorly correlated
N/A
CGEN - IMAB
27%
Poorly correlated
-0.65%
KPRX - IMAB
27%
Poorly correlated
-1.97%
More